Table 3.
Demographic and clinical characteristics
| US Participants | EU Participants | |||||
|---|---|---|---|---|---|---|
| Dallas, TX (n = 9) | Chicago, IL (n = 7) | Total US (N = 16) | UK (n = 8) | France (n = 8) | Total EU (N = 16) | |
| Age, mean (SD), y | 55.6 (4.3) | 56.4 (3.0) | 55.9 (3.7) | 53.3 (6.5) | 57.4 (4.5) | 55.3 (5.8) |
| Race/ethnicity, n (%) | ||||||
| White | 5 (55.6) | 4 (57.1) | 9 (56.3) | 8 (100) | NDa | NDa |
| Black | 3 (33.3) | 3 (42.9) | 6 (37.5) | 0 | NDa | NDa |
| Hispanic | 1 (11.1) | 0 | 1 (6.3) | 0 | NDa | NDa |
| Highest education level | ||||||
| High school/GED/secondary school | 1 (11.1) | 0 | 1 (6.3) | 3 (37.5) | 5 (62.5) | 8 (50.0) |
| Some college | 3 (33.3) | 2 (28.6) | 5 (31.5) | – | – | – |
| Associates degree (US) or vocational/technical qualifications completed (EU) | 1 (11.1) | 0 | 1 (6.3) | 3 (37.5) | 0 | 3 (18.8) |
| Undergraduate degree | 3 (33.3) | 2 (28.6) | 5 (31.3) | 1 (12.5) | 2 (25.0) | 3 (18.8) |
| Some graduate school | 1 (11.1) | 0 | 1 (6.3) | – | – | – |
| Graduate/professional degree (US) or postgraduate qualification (EU) | 0 | 3 (42.9) | 3 (18.8) | 1 (12.5) | 1 (12.5) | 2 (12.5) |
| BMI, n (%) | ||||||
| < 25 kg/m2 | 2 (22.2) | 2 (28.6) | 4 (25.0) | 2 (25.0) | 3 (37.5) | 5 (31.3) |
| 25.0–29.99 kg/m2 (overweight) | 1 (11.1) | 2 (28.6) | 3 (18.8) | 2 (25.0) | 2 (25.0) | 4 (25.0) |
| 30.0–34.99 kg/m2 (obese class 1) | 2 (22.2) | 2 (28.6) | 4 (25.0) | 4 (50.0) | 2 (25.0) | 6 (37.5) |
| 35.0–39.99 kg/m2 (obese class 2) | 3 (33.3) | 1 (14.3) | 4 (25.0) | 0 | 1 (12.5) | 1 (6.3) |
| ≥ 40.0 (obese class 3) | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
| Comorbid conditions | ||||||
| Hypertension | 2 (22.2) | 2 (28.6) | 4 (25.0) | 0 | 2 (25.0) | 2 (12.5) |
| Mental health condition | 3 (33.3) | 0 | 3 (18.8) | 2 (25.0) | 1 (12.5) | 3 (18.8) |
| Elevated cholesterol | 2 (22.2) | 1 (14.3) | 3 (18.8) | 2 (25.0) | 1 (12.5) | 3 (18.8) |
| Type 2 diabetes | 1 (11.1) | 1 (14.3) | 2 (12.5) | 0 | 0 | 0 |
| Family history of breast cancer | 3 (33.3) | 3 (42.9) | 6 (37.5) | 1 (12.5) | 1 (12.5) | 2 (12.5) |
| Stroke/TIA | 0 | 0 | 0 | 1 (12.5) | 0 | 1 (6.3) |
| Type of menopause | ||||||
| Natural | 8 (88.9) | 7 (100) | 15 (93.8) | 8 (100) | 8 (100) | 16 (100) |
| Surgicalb | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
| Cessation of menses due to breast cancer treatment | 0 | 0 | 0 | 0 | 0 | 0 |
| HT use, n (%) | ||||||
| Current user | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
| Previous user | 3 (33.3) | 3 (42.9) | 6 (37.5) | 0 | 2 (25.0) | 2 (12.5) |
| Never used | 5 (55.6) | 4 (57.1) | 9 (56.3) | 8 (100) | 6 (75.0) | 14 (87.5) |
aCollection of race/ethnicity data was not permitted in France
bBilateral oophorectomy, including hysterectomy
BMI body mass index, GED General Educational Development test, HT hormonal therapy, ND not determined, SD standard deviation, TIA transient ischemic attack